SCHEMBL4239165

SCHEMBL4239165

Cc1n[nH]c(C)c1Oc1ccc(F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 1/20 0.59
ALPL P05186 1/20 0.59
ENPP1 P22413 1/20 0.59
XIAP P98170 1/20 0.59
MEN1 O00255 7/20 0.40
KMT2A Q03164 7/20 0.40
MAPT P10636 6/20 0.40
ALOX12 P18054 4/20 0.40
GAA P10253 3/20 0.40
LMNA P02545 3/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
NAAA Q02083 1/20 0.40
SCN4A P35499 1/20 0.40
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418878 0.82 ENPP3 (0.59) ENPP3ALPLENPP1XIAPMEN1
SCHEMBL4104852 0.78 ENPP3 (0.55) ENPP3ALPLENPP1XIAPMEN1
SCHEMBL17156195 0.78 DHODH (0.43) ENPP3ALPLENPP1XIAPMEN1
SCHEMBL4235277 0.74 AR (0.57) ENPP3ALPLENPP1XIAPMEN1
SCHEMBL4871745 0.73 MEN1 (0.79) MEN1KMT2AMAPTALOX12GAA
SCHEMBL14478842 0.72 MEN1 (0.77) MEN1KMT2AMAPTALOX12GAA
SCHEMBL4884213 0.72 MEN1 (0.77) MEN1KMT2AMAPTALOX12GAA
SCHEMBL509030 0.71 ENPP3 (0.55) ENPP3ALPLENPP1XIAPMEN1
SCHEMBL2448984 0.70 KDR (0.45) ENPP3ALPLENPP1XIAPPTGS1
SCHEMBL4881612 0.70 MEN1 (0.78) MEN1KMT2AMAPTALOX12GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
WO-2009119880-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 WO disclosed
WO-2009119880-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270361-A1 Substituted pyrazole derivatives and use thereof CBR3, CBR1, NOX5 ENPP3 4181/4885ALPL 4724/4885ENPP1 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.